MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/dom.71294

Медицинская библиотека · Diabetes, obesity & metabolism · 2026

Pathway-Specific Polygenic Risk Score and Risk of Hyperglycaemic Progression in Patients With Type 2 Diabetes.

Liu Sylvia, Zheng Huili, Tan Jia Le Ivan, Ang Keven, Zheng Deqiang, Gurung Resham L, Lim Su Chi, Liu Jian-Jun

СтатьяПеревод в очереди

Аннотация

AIM: Pathway-specific polygenic risk scores (psPRS) provide insights into the heterogeneity of type 2 diabetes. We aim to study whether psPRS for beta cell dysfunction, obesity and metabolic syndrome associate with risk of hyperglycaemic progression in Southeast Asian patients with type 2 diabetes.

PARTICIPANTS AND

METHODS

One thousand and fifty-nine insulin-naïve outpatients with type 2 diabetes were enrolled from a secondary hospital and a primary care facility. The psPRS were constructed as a weighted sum of risk alleles associated with specific metabolic pathways. Hyperglycaemic progression was defined as sustained insulin therapy lasting longer than 6 months.

RESULTS

During a median of 11.2 (8.9-11.8) years of follow-up, 188 participants initiated sustained insulin therapy. One SD increment in psPRS for metabolic syndrome was associated with a 17% increased risk for hyperglycaemic progression after adjustment for clinical risk factors (adjusted HR 1.17 [1.02-1.36]). Consistent results were obtained when hyperglycaemic progression was defined as a composite of sustained insulin therapy and requirement for insulin treatments (HbA1c > 8.5% with two or more non-insulin medications). Adding metabolic syndrome psPRS onto clinical risk predictors (diabetes onset age, HbA1c, HDL cholesterol, eGFR, urinary albumin-to-creatinine ratio) did not improve risk discrimination (delta AUC -0.01 [95% CI -0.02 to 0.01], p = 0.50). Neither psPRS for beta cell dysfunction nor obesity was associated with the risk of hyperglycaemic progression.

CONCLUSION

psPRS for metabolic syndrome is nominally associated with risk of hyperglycaemic progression in multi-ancestry Southeast Asian people with type 2 diabetes. The psPRS does not provide incremental value for prediction of hyperglycaemic progression beyond clinical risk predictors.

Для цитирования: Liu Sylvia, Zheng Huili, Tan Jia Le Ivan, Ang Keven, Zheng Deqiang, Gurung Resham L, Lim Su Chi, Liu Jian-Jun. Pathway-Specific Polygenic Risk Score and Risk of Hyperglycaemic Progression in Patients With Type 2 Diabetes.. Diabetes, obesity & metabolism. 2026. DOI: 10.1111/dom.71294.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.